[1]
|
Santra, A., Chowdhury, A., Chaudhury, S., et al. (2000) Oxidative stress in gastric mucosa in Helicobacter pylori infection. Indian Journal of Gastroenterology, 19, 21-23.
|
[2]
|
Hayashi, S., Sugiyama, T., Amano, K., Isogai, H., Isogai, E., Aihara, M., et al. (1998) Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrobial Agents and Chemotherapy, 42, 1895-1889.
|
[3]
|
Urita, Y., Watanabe, T., Maeda, T., Sasaki, Y., Hike, K., Muto, H., et al. (2009) Rebamipide and mosapride enhance pilocarpine-induced salivation. North American Journal of Medical Sciences, 1, 121-124.
|
[4]
|
Chey, W.D. and Wong, B.C. (2007) Practice parameters committee of the American College of Gastroenterology: American College of Gastroenterology guideline on the management of Helicobacter pylori infection. American Journal of Gastroenterology, 102, 1808-1825.
doi:10.1111/j.1572-0241.2007.01393.x
|
[5]
|
Chitapanarux, T., Praisontarangkul, O.A. and Lertpraser tsuke, N. (2008) An open-labeled study of rebamipide treatment in chronic gastritis patients with dyspeptic symptoms refractory to proton pump inhibitors. Digestive Diseases and Sciences, 53, 2896-2903.
doi:10.1007/s10620-008-0255-5
|
[6]
|
Naito, Y., Yoshikawa, T., Tanigawa, T., et al. (1995) Hydroxyl radical scavenging by rebamipide and related compounds: Electron paramagnetic resonance study. Free Radical Biology & Medicine, 18, 117-123.
doi:10.1016/0891-5849(94)00110-6
|
[7]
|
Arakawa, T., Kobayashi, K., Yoshikawa, T., Tarnawski, A. (1998) Rebamipide: Overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Digestive Diseases and Sciences, 43, 5S-13S.
|
[8]
|
Rugge, M. and Genta, R.M. (2005) Staging and grading of chronic gastritis. Human Pathology, 36, 228-233.
doi:10.1016/j.humpath.2004.12.008
|
[9]
|
Naito, Y., Yoshikawa, T., Iinuma, S., Yagi, N., Matsu yama, K., Boku, Y., Fujii, T., Yoshida, N., Kondo, M. and Sasaki, E. (1998) Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in double-blind, placebo-controlled study. Digestive Diseases and Sciences, 43, 83S-89S.
|
[10]
|
Higuchi, K., Arakawa, T., Nebiki, H., Uchida, T., Fujiwara, Y., et al. (1998) Rebamipide prevents recurrence of gastric ulcers without affecting Helicobacter pylori status. Digestive Diseases and Sciences, 43, S99-S106.
|
[11]
|
Miwa, T., Osada, T., Nagahara, A., Ohsuka, T., Hojo, M., Tomita, T., et al. (2006) Effect of a gastro-protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia: A double-blind placebo-controlled study in Japan. Journal of Gastroenterology and Hepatology, 21, 1826-1831.
doi:10.1111/j.1440-1746.2006.04446.x
|
[12]
|
Jeffery, P.L., McGuckin, M.A. and Linde, S.K. (2011) Endocrine impact of Helicobacter pylori: Focus on ghrelin and ghrelin o-acyltransferase. World Journal of Gastroenterology, 17, 1249-1260.
doi:10.3748/wjg.v17.i10.1249
|
[13]
|
Du, Y., Li, Z., Zhan, X., Chen, J. and Gao, J. (2008) Anti inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: A randomized sucralfate-controlled multicenter trial in China-STARS study. Digestive Diseases and Sciences, 53, 2886-2895. doi:10.1007/s10620-007-0180-z
|
[14]
|
Everett, S.M., Singh, R., Leuratti, C. et al. (2001) Levels of malondialdehyde-deoxyguanosine in the gastric mucosa: Relationship with lipid peroxidation, ascorbic acid, and Helicobacter pylori. Cancer Epidemiology, Biomarkers & Prevention, 10, 369-376.
|
[15]
|
Naito, Y., Takagi, T., Okada, H., et al. (2009) Impaired gastric ulcer healing in diabetic mice: Role of methylglyoxal. Journal of Physiology and Pharmacology, 60, 123-130.
|